Showing results (1561-1570 of 2,171) with videos related to

Sort By:
Pageof 218
European Heart Journal|February 8, 2003
Time-based risk assessment after myocardial infarction. Implications for timing of discharge and applications to medical decision-makingL K Newby, V Hasselblad, P W Armstrong, et al.
Transplantation|April 29, 2004
Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole bloodMarkus J Barten, Frank Streit, Martin Boeger, et al.
Therapeutic Drug Monitoring|March 30, 2005
Mycophenolic acid interaction with cyclosporine and tacrolimus in vitro and in vivo: evaluation of additive effects on rat blood lymphocyte functionMarkus J Barten, Maria Shipkova, Peter Bartsch, et al.
Travel Medicine and Infectious Disease|December 1, 2009
Outcomes of diarrhea management in operations Iraqi Freedom and Enduring FreedomJamey A Brown, Mark S Riddle, Shannon D Putnam, et al.
Dermatology and Therapy|July 29, 2025
Brodalumab: Seven-Year US Pharmacovigilance ReportMark G Lebwohl, John Y Koo, April W Armstrong, et al.
American Heart Journal|July 29, 2014
Association of metabolic syndrome and its individual components with outcomes among patients with high-risk non-ST-segment elevation acute coronary syndromesRajendra H Mehta, Cynthia M Westerhout, Yinggan Zheng, et al.
Dermatology and Therapy|December 30, 2022
Real-World Effectiveness of 9-12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis RegistryApril W Armstrong, Timothy Fitzgerald, Robert R McLean, et al.
The Journal of Rheumatology|March 16, 2021
Report of the Skin Research Working Groups From the GRAPPA 2020 Annual MeetingLourdes M Perez-Chada, Alison Kohn, Alice B Gottlieb, et al.
Advances in Therapy|March 17, 2023
The Effectiveness of Guselkumab by BMI Category Among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis RegistryApril W Armstrong, Timothy Fitzgerald, Robert R McLean, et al.
Dermatology and Therapy|May 9, 2024
Brodalumab: 5-Year US Pharmacovigilance ReportMark G Lebwohl, John Y Koo, April W Armstrong, et al.
Pageof 218